However, it is plausible to speculate that there may be a synergistic effect of obesity on T2D risk in relation to the SLC30A8 variant, potentially driven by the combined impact of lower insulin secretion and obesity-associated elevations in glucose levels and insulin resistance. The gene discussed is INS; the disease is obesity disorder.